Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies

Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies

Modern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, including left ventricular dysfunction, heart failu...

Full description

Bibliographic Details
Main Authors: Anastasia Stella Perpinia, Nikolaos Kadoglou, Maria Vardaka, Georgios Gkortzolidis, Apostolos Karavidas, Theodoros Marinakis, Chrysostomi Papachrysostomou, Panagiotis Makaronis, Charikleia Vlachou, Marina Mantzourani, Dimitrios Farmakis, Konstantinos Konstantopoulos
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Pharmaceuticals
Subjects:
leukemia
lymphoma
cardiotoxicity
heart failure
anthracyclines
anticancer targeted therapies
Online Access:https://www.mdpi.com/1424-8247/15/8/1007

Internet

https://www.mdpi.com/1424-8247/15/8/1007

Similar Items